CN108969511A - Bromhexine and its derivative are treating and preventing the application on eye surface diseases - Google Patents
Bromhexine and its derivative are treating and preventing the application on eye surface diseases Download PDFInfo
- Publication number
- CN108969511A CN108969511A CN201810764764.6A CN201810764764A CN108969511A CN 108969511 A CN108969511 A CN 108969511A CN 201810764764 A CN201810764764 A CN 201810764764A CN 108969511 A CN108969511 A CN 108969511A
- Authority
- CN
- China
- Prior art keywords
- bromhexine
- derivative
- application
- eye surface
- surface diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bromhexine and its derivative are treating and preventing the application on eye surface diseases, the purpose of the present invention is to provide a kind of new purposes, technical solution provided by the invention is as follows: the solution of the present invention is: providing a kind of bromhexine and its derivative is treating and preventing the application on xerophthalmia and other eye surface diseases.Beneficial effects of the present invention and excitation are, bromhexine and its derivative can stimulate conjunctival epithelium secreting liquid (water in ocular, electrolytic salt) and mucoprotein (MUC5AC) ingredient, and then safeguard and promote the balance of ocular tear microenvironment and health and achieve the purpose that treating eye surface diseases includes xerophthalmia.Furthermore, the clinical practice applied outside eye over the years proves that bromhexine and its derivative may also have the function of analgesic analgesia and anti-inflammatory, it includes xerophthalmia bring ophthalmic uncomfortable and corresponding ocular inflammation that these function poles, which can further decrease eye surface diseases, and then more improve, safeguard and promote the balance and health of ocular tear microenvironment.
Description
Technical field
The present invention relates to a kind of new applications of drug, and in particular to be bromhexine and its derivative treat and prevent it is dry
Application on eye disease and other eye surface diseases.
Background technique
Xerophthalmia can lead to ophthalmic uncomfortable, visual disorders even visual loss because of the damage to ocular.It is estimated that in the U.S.
In crowd more than 50 years old, there are about 5,000,000 men and women to suffer from xerophthalmia, the case where other countries of the world should the minimum and U.S. differ
It is very few.Expenditure related with dry eyes is about 38.4 hundred million dollars to American Medical Systems every year, whole society related with dry eyes of the U.S.
Then there are about as many as 55,400,000,000 dollars for the annual conversion of burden.In mobile phone, computer essential present age for people's lives, xerophthalmia meeting
Influence each age interval crowd with getting worse, have been identified as at present epochmaking social public health problem it
One.
Mainly include at present following several means to the treatment of dry eyes, protects ocular lubricant (including the artificial tear of mucous membrane
Liquid), Punctal plug, anti-ocular inflammation medicine and water mucoprotein stimulant.Even so, the illness of many xerophthalmia can not obtain
Adequately alleviate.The frequency put drops in one's eyes is excessively high not only to be will increase expense but also is also not easily achieved for many patients.
Currently, the most common purposes of bromhexine is as expectoration dissolving phlegm medicine, for the respiratory disease excessive with mucus
In, such as the important activity ingredient in cough syrup, bromhexine is also possible to local analgesia, anti-inflammatory effects, there is no about
It may be used as treating and preventing the application on xerophthalmia and other eye surface diseases.
Summary of the invention
The purpose of the present invention is to provide a kind of new purposes, technical solution provided by the invention is as follows:
The solution of the present invention is: providing a kind of bromhexine and its derivative and is treating and preventing xerophthalmia and other oculars
Application in disease.
The molecular structure of bromhexine is shown in as follows:
The derivative of bromhexine includes the molecule being derived from its main molecules framework, such as the chloride of bromhexine
The derivative that (Bromhexine Chloride) further includes following essential molecular structure and is generated by it:
One of its application is: the bromhexine and its derivative is as treatment xerophthalmia and the medicine of other eye surface diseases
The active constituent of object.
Above-mentioned pharmaceutical dosage form can be solution (solutions), glue (gel), dropping liquid (drop), cream (ointment),
Suspension (suspension), micro emulsion (microemulsion), nano particle (nanoparticle), liposome
(liposome), lotion (lotion) pastes (paste) or similar dosage form.It includes 0.01% to 20% (w/ using concentration range
W and/or w/v), usual range is 0.5% to 5% (w/w and/or w/v).
It two is using it: the application is degradable or can not to mix or being integrated into bromhexine and its derivative
Certain polymer (polymer) carrier of degradation reaches the mesh of permanent and/or controllable release so that certain sustained-release dosage type is made
's.The carrier of this sustained-release dosage type includes but is not limited to external pump, contact lens, Punctal plug, can be attached to ocular (cornea,
Conjunctiva) mucous membrane tablet (tablet), pill (pill, pellet), capsule (capsule), particle (particle), gypsum
Plate (plaster), joint strip (strips) or the like；It can be inserted into or be imbedded at conjunctiva, under conjunctiva, the implantation of fascia under conjunctiva
Body (inserts) or sustained release reservoir (depots) and other forms ophthalmically acceptable injection, implant (inserts) or
It is sustained reservoir (depots).The above-mentioned dosage form that can be administered through ocular, such as eyedrops, eye ointment, eye glue is a kind of, bromhexine and its
The dosage rate of derivative can be according to drug effect situation from once differing to every ten minutes once a day.It is degradable or can not when being integrated into
For when being sustained purpose, the application frequency of bromhexine and its derivative can then to be reduced, dosage rate in the polymeric carrier of degradation
Range is about from primary to even every half a year four times per day.
Polymer for making slow-released carrier need to have good biological compatible, they include but is not limited to following chemical combination
Object: more poly 2-hydroxyethyl methacrylate rouge glues (p-HEMA hydrogel), poly lactide-glycolide acid (PLGA),
Polycaprolactone (PCL), hydroxypropyl cellulose (Hydroxypropyl cellulose), NSC 24345 (AnA), gelatin
(gelatin) or collagen (collagen) etc..
The beneficial effects of the present invention are, bromhexines and its derivative can stimulate conjunctival epithelium secreting liquid in ocular
(water, electrolytic salt) and mucoprotein (MUC5AC) ingredient, so safeguard and promote ocular tear microenvironment balance and health and
Achieve the purpose that treating eye surface diseases includes xerophthalmia.In addition, the clinical practice applied outside eye over the years proves bromhexine
And its derivative may also have the function of analgesic analgesia and anti-inflammatory, it includes dry that these function poles, which can further decrease eye surface diseases,
Eye disease bring ophthalmic uncomfortable and corresponding ocular inflammation, and then more improve, safeguard and promote the flat of ocular tear microenvironment
Weighing apparatus and health.
Detailed description of the invention
Fig. 1 is the comparison diagram that bromhexine handles people's original conjunctival epithelial cell AQP5 and MUC5AC mRNA after 24 hours；
Fig. 2 is the comparison diagram of the expression of MUC5AC albumen after bromhexine handles people's original conjunctival epithelium carefully.
Specific embodiment
Embodiment 1
Healthy People fornical conjunctiva tissue is taken, (≤1mm) is shredded in PBS, clostridiopetidase A and dispersion is added after being centrifuged off PBS
Enzyme is digested, and acquisition is unicellular, and supernatant containing enzyme is removed in centrifugation, and the DMEM containing 10% fetal calf serum is utilized to carry out adherent training
It supports, takes 5 μM of bromhexine processing primary conjunctival epithelial cells of people in 37 DEG C of CO2Incubator culture 24 hours, control group was extracted respectively
The RNA of (not doing above-mentioned bromhexine processing) and bromhexine processing group cell, carries out fluorescence quantitative PCR detection aquaporin
The variation that AQP5 and mucoprotein MUC5AC are expressed in mRNA level in-site.
As a result as shown in Figure 1,5 μM of bromhexines are handled 24 hours, people primary conjunctival epithelial cell AQP5 and MUC5AC occur
Obvious up-regulation, and there is not the case where up-regulation in control group.
It is collected simultaneously the albumen of control cell Yu bromhexine processing group cell, Western blot is carried out and detects MUC5AC
The expression of albumen changes.As a result as shown in Figure 2, it will thus be seen that 5 μM of bromhexines are handled 24 hours, the primary conjunctival epithelial cell of people
Middle MUC5AC protein expression is obviously raised, and control group is raised not as good as bromhexine processing group.
There is stimulation AQP5 and MUC5AC really with the conjunctiva primary cultured cell experimental verification of people and mouse bromhexine
Mucoprotein expresses raised effect.
Conjunctiva can with secreting liquid, and secretion intensity be can be increased by stimulation, from conjunctiva source
Liquid is the important component of ocular tear.The research in applicant laboratory has a unique discovery in recent years, with osmotic pressure gradient
What it is for power is mainly to pass through aquaporin (Aquaporins, AQPs) progress through conjunctiva fluid transport, this through conjunctiva
Fluid transport to maintain ocular tear amount and normal tear osmotic pressure it is extremely important.Applicant research department current research data
Prove that the raising of AQP5 expression can drive the generation and secretion for increasing conjunctival epithelium MUC5AC mucoprotein simultaneously, and MUC5AC glues egg
White specially produced by cup cell is secreted, and epochmaking colloid mucoprotein in tear is belonged to.It therefore, can be by stimulating AQPs table
The compound reached reinforces the fluid transport through conjunctiva, safeguards the balance of ocular tear quality and quantity, while also can increase in glass cell
The production of MUC5AC mucoprotein is secreted, and becomes the good drug for the treatment of dry eyes.
Embodiment 2
A kind of eye drops, wherein the content of bromhexine is 0.35% (w/w), and the pH value of eye drops is 6.5, and osmotic pressure ratio is
1.0, osmotic pressure ratio when which refers to compared with physiological saline.
Object using above-mentioned eye drops is commonly using patients with dry eye caused by electronic product in use, every time to list
The eye drip amount of eye is dripped for 2, and one day 3-6 times.After continuous use 15 days, Schimer's test value be increased, and the disease of xerophthalmia
Shape is greatly improved.
Claims (7)
1. a kind of drug containing bromhexine and its derivative is treating and preventing the application on xerophthalmia and other eye surface diseases.
2. application according to claim 1, which is characterized in that the bromhexine and its derivative are as treatment xerophthalmia
And the active constituent of the drug of other eye surface diseases.
3. application according to claim 1, which is characterized in that the dosage form of the drug is solution, glue, dropping liquid, cream, hangs
Supernatant liquid, micro emulsion, nano particle, liposome, lotion, paste or similar dosage form.
4. application according to claim 1, which is characterized in that the concentration range of the application is 0.01% to 20%.
5. application according to claim 4, which is characterized in that the concentration range of the application is 0.5% to 5%.
6. application according to claim 1, which is characterized in that the application is by the bromhexine and its derivative
It mixes or is integrated into carrier with manufactured sustained-release dosage type.
7. application according to claim 6, which is characterized in that the carrier is external pump, contact lens, lacrimal point
Plug, or the tablet of ocular mucous membrane, pill, capsule, particle, plasterboard, joint strip can be attached to or the like, or can be inserted into or heeling-in
The implant of fascia or sustained release reservoir or the ophthalmically acceptable injections of other forms under conjunctiva, conjunctiva and under conjunctiva, implant or
It is sustained reservoir.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810764764.6A CN108969511A (en) | 2018-07-12 | 2018-07-12 | Bromhexine and its derivative are treating and preventing the application on eye surface diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810764764.6A CN108969511A (en) | 2018-07-12 | 2018-07-12 | Bromhexine and its derivative are treating and preventing the application on eye surface diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108969511A true CN108969511A (en) | 2018-12-11 |
Family
ID=64537915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810764764.6A Pending CN108969511A (en) | 2018-07-12 | 2018-07-12 | Bromhexine and its derivative are treating and preventing the application on eye surface diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108969511A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089797A1 (en) * | 2016-11-14 | 2018-05-17 | Mingwu Wang | Formulations for the treatment of ocular surface diseases and related methods |
-
2018
- 2018-07-12 CN CN201810764764.6A patent/CN108969511A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089797A1 (en) * | 2016-11-14 | 2018-05-17 | Mingwu Wang | Formulations for the treatment of ocular surface diseases and related methods |
Non-Patent Citations (2)
| Title |
|---|
| 刘凤 等: "溴苄环己胺治疗干眼症的疗效评价", 《天津医药》 * |
| 张然 等: "使用盐酸溴己新片联合聚乙二醇滴眼液治疗干眼症的效果观察", 《当代医药论丛》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103167850B (en) | Ion-transmission cornea is utilized to transmit the device of riboflavin treatment keratoconus | |
| Hu et al. | A novel approach for subretinal implantation of ultrathin substrates containing stem cell-derived retinal pigment epithelium monolayer | |
| CN107106613A (en) | For the composition for including source of human stem cell excretion body into fat induction, adipose tissue regeneration, skin-whitening or improvement wrinkle | |
| CN105267240A (en) | Applications of exosome from mesenchymal stem cells | |
| Juliana et al. | Promising approach in the treatment of glaucoma using nanotechnology and nanomedicine-based systems | |
| Liao et al. | 3D Ti3C2T x MXene–Matrigel with Electroacoustic Stimulation to Promote the Growth of Spiral Ganglion Neurons | |
| CN109045063A (en) | A kind of injecting temperature sensitive in situ response water soluble chitosan composite hydrogel and its preparation method and application for lacrimal passage embolism | |
| Buss et al. | Efficacy and safety of mitomycin C as an agent to treat corneal scarring in horses using an in vitro model | |
| Cegielska et al. | Targeted drug delivery systems for the treatment of glaucoma: Most advanced systems review | |
| Xu et al. | Preparation and characterization of ion-sensitive brimonidine tartrate in situ gel for ocular delivery | |
| Yin et al. | Zinc oxide nanoparticles ameliorate collagen lattice contraction in human tenon fibroblasts | |
| Schaffrath et al. | New epiretinal implant with integrated sensor chips for optical capturing shows a good biocompatibility profile in vitro and in vivo | |
| CN110013498A (en) | A kind of eye drops and preparation method thereof of hydrochloric olopatadine | |
| Shen et al. | In Situ Formation of Injectable Gelatin Methacryloyl (GelMA) Hydrogels for Effective Intraocular Delivery of Triamcinolone Acetonide | |
| CN108969511A (en) | Bromhexine and its derivative are treating and preventing the application on eye surface diseases | |
| Wani et al. | Promising role of silk-based biomaterials for ocular-based drug delivery and tissue engineering | |
| CN107151263A (en) | A kind of small peptide inhibitor for suppressing amylin aggregation | |
| CN108785308B (en) | application of antagonist of nuclear receptor Rev-erb α in preparation of anti-abdominal aortic aneurysm drugs | |
| CN103006706B (en) | Amniotic membrane liposome for ocular surface reconstruction and preparation method and application thereof | |
| CN115919804A (en) | Nano-carrier system for inducing Treg cell differentiation and application of nano-carrier system in RA treatment | |
| Ramsden et al. | Stemming the tide of age-related macular degeneration: new therapies for old retinas | |
| Prox et al. | Toward living neuroprosthetics: Developing a biological brain pacemaker as a living neuromodulatory implant for improving parkinsonian symptoms | |
| CN103330945A (en) | Application of pingyangmycin combined with sodium hyaluronate in drug for treating lymphatic malformation | |
| CN112891326A (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| CN110025818A (en) | A kind of chitosan piezoelectric membrane and the preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181211 |